Niu Yanlin, Wang Shengchao, Deng Xinzhou, Luo Ming, Chai Jingjing, Luo Zhiguo
Department of Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Key Laboratory of Cancer Therapy Resistance and Clinical Translational Study, Shiyan, Hubei, China.
Front Immunol. 2025 Aug 8;16:1645909. doi: 10.3389/fimmu.2025.1645909. eCollection 2025.
Renal squamous cell carcinoma (RSCC) is an uncommon malignancy, representing less than 1% of all renal cancers, and is associated with a notably poor prognosis. Surgical intervention is the primary treatment modality for early and intermediate-stage cases; however, the efficacy of combined chemoradiotherapy and immunotherapy in advanced-stage patients remains unclear. In this report, we present a case of RSCC with pulmonary metastases, wherein the patient attained disease remission following a treatment regimen comprising combined chemo-radiotherapy and immunotherapy. The patient demonstrated a progression-free survival (PFS) of 12 months and an overall survival (OS) of 14 months. This case study aims to provide a comprehensive analysis of the treatment approach, potentially serving as a reference for therapeutic strategies in patients with inoperable RSCC.
肾鳞状细胞癌(RSCC)是一种罕见的恶性肿瘤,占所有肾癌的比例不到1%,且预后明显较差。手术干预是早期和中期病例的主要治疗方式;然而,晚期患者联合放化疗和免疫治疗的疗效仍不明确。在本报告中,我们介绍了一例伴有肺转移的RSCC病例,该患者在接受联合放化疗和免疫治疗的方案后病情缓解。患者的无进展生存期(PFS)为12个月,总生存期(OS)为14个月。本病例研究旨在对治疗方法进行全面分析,可能为无法手术的RSCC患者的治疗策略提供参考。